Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Dynamic Epigenetic Landscape in Genetic and Immunophenotypic Stable Pediatric AML

Diana Hanekamp, MSc, Jennifer R. Scheick, Yaseswini Neelamraju, Edwin Sonneveld, PhD, Valerie de Haas, MD PhD, Gert J. Ossenkoppele, MD PhD, Gerrit J. Schuurhuis, PhD, Gertjan J.L. Kaspers, MD PhD, Francine E. Garrett-Bakelman, MDPhD, Jacqueline Cloos, PhD

Blood (2017) 130 (Supplement 1): 2686.

https://doi.org/10.1182/blood.V130.Suppl_1.2686.2686

Published: 2017

Journal Articles

MicroRNA Expression Profiling of Hematopoietic and Leukemic Stem Cells in Acute Myeloid Leukemia,

David C. de Leeuw, MD, Fedor Denkers, Gerrit J. Schuurhuis, PhD, Gert J Ossenkoppele, MD, PhD, Linda Smit, PhD

Blood (2011) 118 (21): 3999.

https://doi.org/10.1182/blood.V118.21.3999.3999

Published: 2011

Journal Articles

Combination of CD34/CD38 Immunophenotypes and Side Population (SP) Reveals the Putative Leukemia Stem Cell/Leukemia Initiating Cell In Acute Myeloid Leukemia.

Gerrit J Schuurhuis, PhD, Bijan Moshaver, Alexander N Snel, Gert J. Ossenkoppele, MD, PhD, Sonja Zweegman, MD, PhD

Blood (2010) 116 (21): 1582.

https://doi.org/10.1182/blood.V116.21.1582.1582

Published: 2010

Journal Articles

Specificity of Markers of Leukemia Initiating Cells with a New Multiparameter Flow Cytometry Based Appraoch; Impact for Prognostic and Therapeutic Applications

Gerrit J. Schuurhuis, PhD, Rolf Wouters, Angèle Kelder, Arjo P Rutten, Alexander N Snel, Monique Terwijn, Paul Noordhuis, PhD, Sonja Zweegman, MD, PhD, Gert J. Ossenkoppele, MD, PhD

Blood (2010) 116 (21): 1834.

https://doi.org/10.1182/blood.V116.21.1834.1834

Published: 2010

Journal Articles

High Prognostic Impact of Flowcytometric Minimal Residual Disease Detection In Acute Myeloid Leukemia: Prospective Data From the HOVON/SAKK 42a Study

Monique Terwijn, Angèle Kelder, Wim L.J. van Putten, Alexander N. Snel, Vincent H.J. van der elden, PhD, Rik A. Brooimans, PhD, Nancy Boeckx, MD, PhD, Frank W.M.B. Preijers, PhD, Bob Löwenberg, MD, PhD, Angelika M. Dräger, PhD, Peter C. Huijgens, MD, PhD, Peter J.M Valk, PhD, Johan Maertens, MD, Thomas Pabst, MD, PhD, Gert J. Ossenkoppele, MD, PhD, Gerrit J. Schuurhuis, PhD

Blood (2010) 116 (21): 760.

https://doi.org/10.1182/blood.V116.21.760.760

Published: 2010

Journal Articles

Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody

Paul Noordhuis, PhD, Monique Terwijn, Arjo P Rutten, Linda Smit, PhD, Gert J. Ossenkoppele, MD, PhD, Gerrit J. Schuurhuis, PhD

Blood (2010) 116 (21): 2890.

https://doi.org/10.1182/blood.V116.21.2890.2890

Published: 2010

Journal Articles

The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved

Gerrit J. Schuurhuis, PhD, Angèle Kelder, Monique Terwijn, Arjo P Rutten, Linda Smit, PhD, Sonja Zweegman, MD, PhD, Gert Ossenkoppele, MD, PhD

Blood (2010) 116 (21): 2725.

https://doi.org/10.1182/blood.V116.21.2725.2725

Published: 2010

Journal Articles

High Aldehyde Dehydrogenase Activity (ALDH) Is a General Marker for Normal Hematopoietic Stem Cells but Not Leukemic Stem Cells in Acute Myeloid Leukemia (AML). .

Linda Smit, PhD, Lisa A Min, Monique Terwijn, Angele Kelder, Alexander N Snel, Gert J Ossenkoppele, MD, PhD, Gerrit J. Schuurhuis, PhD

Blood (2009) 114 (22): 4035.

https://doi.org/10.1182/blood.V114.22.4035.4035

Published: 2009

Journal Articles

Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse

Costa Bachas, MSc, Gerrit J. Schuurhuis, PhD, Lê D Huynh, BSc, Bianca F. Goemans, MD, PhD, D. Reinhardt, MD, PhD, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2008) 112 (11): 2540.

https://doi.org/10.1182/blood.V112.11.2540.2540

Published: 2008

Journal Articles

Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia.

Bijan Moshaver, Angele Kelder, Guus Westra, Anna van Rhenen, MD, Gert J. Ossenkoppele, MD, PhD, Sonja Zweegman, MD, PhD, Gerrit J. Schuurhuis, PhD

Blood (2007) 110 (11): 4120.

https://doi.org/10.1182/blood.V110.11.4120.4120

Published: 2007

Journal Articles

In Acute Myeloid Leukemia Both Malignant and Normal Stem Cells Can Be Detected in Remission Bone Marrow.

Anna van Rhenen, Nicole Feller, PhD, Angele Kelder, Bijan Moshaver, Sonja Zweegman, PhD MD, Gert Ossenkoppele, PhD MD, Gerrit J. Schuurhuis, PhD

Blood (2006) 108 (11): 2537.

https://doi.org/10.1182/blood.V108.11.2537.2537

Published: 2006

Journal Articles

Identification of Primitive Subpopulations of Acute Myeloid Leukemia Side Population (SP) Stem Cells Defined by Differentiation Status and Malignant Character.

Bijan Moshaver, Marjolein A. van der Pol, PhD, Guus H. Westra, Nicole Feller, PhD, Angele Kelder, Anna van Rhenen, Gert J. Ossenkoppele, MD,PhD, Sonja Zweegman, MD,PhD, Gerrit J. Schuurhuis, PhD

Blood (2006) 108 (11): 2538.

https://doi.org/10.1182/blood.V108.11.2538.2538

Published: 2006

Journal Articles

Acute Myeloid Leukemia Remission Bone Marrow Reveals the Presence of Malignant and Normal Side Population (SP) Stem Cells Whose Frequencies and Ratios Predict Clinical Outcome.

Bijan Moshaver, Marjolein A. van der Pol, PhD, Guus H. Westra, Nicole Feller, PhD, Angele Kelder, Anna van Rhenen, Gert J. Ossenkoppele, MD,PhD, Sonja Zweegman, MD,PhD, Gerrit J. Schuurhuis, PhD

Blood (2006) 108 (11): 2314.

https://doi.org/10.1182/blood.V108.11.2314.2314

Published: 2006

Journal Articles

Immunophenotypical Sequential MRD Assessment in AML for Prediction of Relapse and Definition of Putative Future Intervention Time Points.

Nicole Feller, Peter C. Huijgens, MD, PhD, Angele Kelder, Guus Westra, Gert Ossenkoppele, MD, PhD, Gerrit J. Schuurhuis, PhD

Blood (2004) 104 (11): 3012.

https://doi.org/10.1182/blood.V104.11.3012.3012

Published: 2004

Journal Articles

Identification of Genes Potentially Involved in Disease Transformation of CML.

Jeroen J. Janssen, MD, S. Marjolein Klaver, Msc, Quinten Waisfisz, PhD, Gerard Pasterkamp, MD, PhD, Dominique P. de Kleijn, MD, PhD, Gerrit J. Schuurhuis, PhD, Gerrit J. Ossenkoppele, MD, PhD

Blood (2004) 104 (11): 2950.

https://doi.org/10.1182/blood.V104.11.2950.2950

Published: 2004

NARROW

A Dynamic Epigenetic Landscape in Genetic and Immunophenotypic Stable Pediatric AML

MicroRNA Expression Profiling of Hematopoietic and Leukemic Stem Cells in Acute Myeloid Leukemia,

Combination of CD34/CD38 Immunophenotypes and Side Population (SP) Reveals the Putative Leukemia Stem Cell/Leukemia Initiating Cell In Acute Myeloid Leukemia.

Specificity of Markers of Leukemia Initiating Cells with a New Multiparameter Flow Cytometry Based Appraoch; Impact for Prognostic and Therapeutic Applications

High Prognostic Impact of Flowcytometric Minimal Residual Disease Detection In Acute Myeloid Leukemia: Prospective Data From the HOVON/SAKK 42a Study

Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody

The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved

High Aldehyde Dehydrogenase Activity (ALDH) Is a General Marker for Normal Hematopoietic Stem Cells but Not Leukemic Stem Cells in Acute Myeloid Leukemia (AML). .

Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse

Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia.

In Acute Myeloid Leukemia Both Malignant and Normal Stem Cells Can Be Detected in Remission Bone Marrow.

Identification of Primitive Subpopulations of Acute Myeloid Leukemia Side Population (SP) Stem Cells Defined by Differentiation Status and Malignant Character.

Acute Myeloid Leukemia Remission Bone Marrow Reveals the Presence of Malignant and Normal Side Population (SP) Stem Cells Whose Frequencies and Ratios Predict Clinical Outcome.

Immunophenotypical Sequential MRD Assessment in AML for Prediction of Relapse and Definition of Putative Future Intervention Time Points.

Identification of Genes Potentially Involved in Disease Transformation of CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only